AI Automation for Pharma & Biotech Laboratories

Electronic records and signatures must meet 21 CFR Part 11 requirements — audit trails, access controls, validation documentation. Every system change requires re-validation. Labs spend months on IQ/OQ/PQ protocols that could be streamlined with automation.

QC analysts spend nearly half their time documenting results, reviewing deviations, and completing batch records — not running tests. Paper-based or semi-electronic batch records create bottlenecks at every review step.

ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate) require airtight data flows. Manual transcription between instruments and LIMS creates data integrity risks. FDA inspectors increasingly focus on electronic data governance.

Transferring analytical methods between R&D and manufacturing — or between sites — requires extensive documentation, parallel testing, and validation. Manual processes extend timelines and delay product launches.

Global pharma and biotech companies run labs across multiple sites, each with slightly different systems, SOPs, and workflows. Harmonization efforts stall because manual processes cannot be replicated exactly across locations.